InflaRx (IFRX) Other Non Operating Income (2017 - 2026)
InflaRx (IFRX) posted Other Non Operating Income of $940296.1 for Q1 2026, down 92.29% sequentially from $12.2 million in Q4 2025, and down 85.37% YoY from $6.4 million in Q1 2025.
InflaRx (IFRX) Other Non Operating Income (2017 - 2026) Analysis & Trends
InflaRx has reported Other Non Operating Income for 10 years, with the latest figure at $940296.1 in Q1 2026.
- Quarterly Other Non Operating Income fell 85.37% year-over-year to $940296.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 25.68% YoY) and the FY2025 annual result came in at $6.4 million, up 61.66% from the prior year.
- Other Non Operating Income slipped to $940296.1 in Q1 2026 per IFRX's latest filing, from $12.2 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $12.2 million in Q4 2025 and troughed at -$1220.7 billion in Q1 2023.
- A 5-year average of -$71.8 billion and a median of $835908.5 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income surged 267.67% in 2022, then tumbled 149417763.85% in 2023.
- Over 5 years, Other Non Operating Income stood at -$746398.7 in 2022, then sank by 442.75% to -$4.1 million in 2023, then soared by 205.04% to $4.3 million in 2024, then jumped by 186.79% to $12.2 million in 2025, then slumped by 92.29% to $940296.1 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $940296.1, $12.2 million, and -$3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 940,296.08 |
| Dec 31, 2025 | 12.20 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Mar 31, 2025 | 6.43 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Sep 30, 2024 | -3.13 Mn |
| Jun 30, 2024 | 766,109.67 |
| Mar 31, 2024 | 1.98 Mn |
| Dec 31, 2023 | -4.05 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Jun 30, 2023 | 835,908.45 |
| Mar 31, 2023 | -1,220.72 Bn |
| Dec 31, 2022 | -746,398.69 |
| Sep 30, 2022 | 889,671.02 |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 816,986.66 |
| Dec 31, 2021 | 2,246.91 Bn |
| Sep 30, 2021 | 844,132.69 |
| Jun 30, 2021 | -995,093.10 |